Audrey’s Selected Meeting List for January 2008



Audrey’s Life Science Meeting Picks for March –April 2010

(March 20th Edition)

***************************************************************

Palo Alto AWIS, Monday Evening, March 22, 2010

Topic: Stem Cells and Women's Health

Speaker: Dr. Reijo Pera

Date and Time: Monday, March 22nd, 2010

Schedule

7:00-7:30 pm Networking and light supper

7:30-7:45 pm Announcements

7:45-8:45 pm Program

8:45-9:00 pm Discussion

Location: PARC Auditorium, 3333 Coyote Hill Road, Palo Alto

RSVP: online 

Topic Description

Dr. Rejio Pera will discuss her research on Stem cells and

reproduction, Women’s somatic health and Women in Cancer.

In recent years, much emphasis has been placed on realizing the promise of stem 

cells in medicine. Yet, little focus has been placed on issues related to women’s

health. We seek to improve women’s health through stem cells.

Stem cells and reproduction

In the USA, reproductive failure carries a cost burden that exceeds $6 billion annually.

Yet, research on reproductive failure, especially on the earliest stages of human

reproduction, has been excluded from federal funding. Our group explored the use of

modern developmental genetic and biophysical means to develop novel diagnostics

and interventions based on scientific evidence. The use of assisted reproductive

techniques to alleviate reproductive failure results in the annual culture of more than a

million embryos. Unfortunately, the vast majority of cases fail to develop properly for

unknown reasons. We have sought to remedy the current state, with studies that will

result in the optimization of embryo culture and diagnosis of germ line and embryo

developmental competence and subsequent fetal and neonatal consequences.

Women’s somatic health

Cardiovascular disease has been the leading cause of death in women for decades;

diabetes and autoimmune diseases disproportionately afflict women and with the

extension of women’s lifespan, degenerative disorders such as urinary incontinence.

Given these facts, a concerted effort to capitalize on the potential of stem cells in

somatic health of women is merited.

Women and Cancer

Several cancers are most frequent or exclusive to women including breast cancer and

ovarian cancer. Promising potential therapies include immunologically-based

therapies and therapies aimed at targeting cancer stem cell populations. Efforts to

focus cancer stem cell efforts on women’s cancer will be discussed.

We have unprecedented opportunity to explore the unique biology of human

development, including that of women, with the advances in stem cell biology

Welcome!!  You don’t need to be a member to attend.

All scientists, students, and their friends are welcome.  Men too!

Members and students pay $5 and non-members pay $10

**********************************************************************

Bio2Device Group, Tuesday Morning, March 23, 2010

Topic: “Starting Out Right:  The Key Legal Considerations in Setting up a Life Sciences Company” 

Speaker: Deborah A. Marshall, Partner, Sidley Austin, LLP

Date and Time: Tuesday, March 23, 2010, 8:30 – 10:30 am

Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)

Cost: Free

Parking: On street and in NOVA and library parking lots across the street.

Topic Description

Silicon Valley is frequently described as a unique ecosystem of entrepreneurs, research institutions, investors and advisors who have developed a common language and way of doing business that enables innovation and growth.  This common language is reflected in the key agreements that every company must put into place in order to effectively create, develop, protect and commercialize its technology.   Join us for a lively discussion of the legal aspects of the startup process.

Speaker Bio

Deborah A. Marshall, a partner with the Sidley firm, concentrates her practice on strategic business counseling for emerging growth companies and investors at all stages of development, from start-up entrepreneurs to publicly traded entities and technology-based, multinational corporations. Ms. Marshall has advised issuers, investors and investment banking firms in the internet, software, electronics, clean technology, media, entertainment, biopharmaceutical, genomics, medical device and diagnostics sectors. She has significant experience in venture capital financing, mergers and acquisitions, public offerings, private equity and strategic partnerships.

Ms. Marshall is a frequent speaker on issues related to venture capital, emerging growth companies, life sciences, public securities and entrepreneurship. She has been a guest lecturer on entrepreneurship at the University of California Berkeley Haas School of Business, as well as a member of the faculty of the Haas Business School’s Global Bio-Executive Program.

Ms. Marshall’s work as a corporate lawyer is highlighted in the 2007 Corporate and Finance version of The Legal 500 United States edition.

************************************************************

BioScience Forum, Wednesday Evening, March 24, 2009

Topic: "Personalized Medicine: Yesterday, Today and Tomorrow. How Genomic Information has, is and will Change Healthcare"

Speaker: Steve Rosenberg, Ph.D., Chief Scientific Officer, CardioDx

Date and Time: Wednesday, March 23, 2010; 6:00pm - 9:00pm

6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentation

Location: The Clarion Hotel, 401 East Millbrae Avenue, Millbrae

Full info and Registration at:



Typical Cost: $50 before 11:55 PM, Monday, March 22nd

$60 on-site

$35 full-time students pre-registration

$45 full-time students on-site

Acteva fees of $3 are added to the above prices Check website for latest information

Cash or check accepted on the day of the event

Parking is $2

 

Or you can pay with a check made out to "BioScience Forum" and sent to:

BioScience Forum, 1442A Walnut Street, #308, Berkeley, CA 94709-1405

Please do not mail checks later than Thursday, March 18th

If paying with check, do not complete registration with Cvent

Topic Description

The ability to decipher genomes started with viruses and bacteria and rapidly moved to eukaryotes and finally to mammals, especially Homo sapiens.  The speed at which this technology has progressed is mind-boggling, from Maxam-Gilbert sequencing in the 70s to single molecule sequencing today.  But how has this tsunami of information benefited human healthcare? Steve will discuss early examples from virology, cite current examples from oncology and cardiovascular diseases, and speculate on what the future may hold.

 

Biography

Steve has been the Chief Scientific Officer at CardioDx, a molecular diagnostics company, focused on the application of genomic information to cardiovascular diseases, since 2006, and led the team which launched Corus CAD™, a blood based gene expression test for the assessment of coronary artery disease, in 2009.  Prior to that he spent three years at XDx, leading the team which developed Allomap™ gene expression testing for detection of rejection in heart transplant recipients.  From 1981 to 2001 Steve occupied positions of increasing responsibility at Chiron Corporation, where he was named one of three Chiron Fellows in the company.  He completed his PhD and post-doctoral work in biochemistry at UC Berkeley.

****************************************************************

BayBio Therapeutic Breakfast Series, Thursday Morning, March 25, 2010

Topic: “Establishing and Successfully Managing Strategic Alliances”

Panel Moderator:  Mike Brasseur, Vice President, Business Solutions, M Squared Consulting, Inc. - Life Sciences

Panel Speakers:   Patrick Bigot, Senior Director, Head of Alliance Management, Genentech, Inc.

Patrice Bruneman, Director, Strategic Alliances, Medivation

Monique Nicoll , Sr. Director, Research & Discovery Alliance Management, Exelixis, Inc.

Venkat Ramanan, Director, International Access Operations, Gilead Sciences, Inc.

Date and Time: Thursday March 25, 2010, 8:00am – 10:00am

Location: Wells Fargo Insurance Services Inc., 305 Walnut Street, Redwood City, CA 94063

Register at:

Event Contact Info: events@

Cost: Through March 23: $10 BayBio and ASAP members, $20 non members; On-site registration March 25: $20 BayBio and ASAP members, $40 non members

Topic Description

The current economic climate, and market pressures are forcing a change in strategy for both established and emerging life sciences companies. The IPO market is gone. The VC funding is dry. Companies, seeking to deliver new treatments and cures, are forming alliances with larger organizations at a faster pace. Some are even saying that we are witnessing a fundamental change, where success will depend on a company's capacity to manage multiple relationships as part of a larger collaborative network. To be successful, companies will need to effectively develop and manage alliances, they must also learn how to remain relevant to their partners and be flexible enough to evolve with changes in the partner's strategy. Join us for a panel of expert Alliance executives to learn how to become "alliance capable" and thrive through collaborations in the new environment.

******************************************************************

San Jose Biocenter, Thursday Afternoon, March 25, 2010

Topic: How to Become a VC Magnet? A Panel & Networking Reception

Panelists:

• Andrew McMillan, Ph.D., Principal, 5AM Ventures - an early-stage VC focused on building next-generation life science companies.

• Rowan Chapman, Partner, Mohr Davidow Ventures - an early stage VC investing in innovative entrepreneurs.

• Wendye Robbins, MD, President & CEO, Limerick BioPharma - which completed a Series C financing, securing $15M in new funds.

• Anthony Ford, Ph.D., Founder & CSO, Afferent Pharmaceuticals - which just received $23M in Series A financing.

• Mickey S. Urdea, Co-Founder, Chairman & CEO, Tethys Bioscience - which recently closed a $25M Series D financing.

• Lead Facilitator: Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP - our Lead Facilitator, and a member of the Emerging Companies Group, which advises emerging companies and VC firms.

Date and Time: Thursday March 25, 2010

• 3:00-3:30 PM Networking and Registration

• 3:30-5:00 PM Expert Panel

• 5:00-6:30 PM Networking Reception

Location: Orrick, Herrington & Sutcliffe LLP, Silicon Valley Office, 1100 Marsh Road, Menlo Park, CA 94025-1015

*Pre-registration closes on March 23rd at noon!*

• Regular Price: $60

• Partners' Network: $50 (Bio2Device Group members eligible for partner network discount; just note B2DG under affiliation)

• BioCenter Members: Free (please RSVP to Aurélie)

• On-site Registration: add $10 to the above

This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!

Register at

Topic Description

Effectively raising capital is crucial for any company. Sufficient capital helps ensuring R&D, Due Diligence, Legal and Accounting services, Marketing, and improves hiring potential. In this session, a panel of VCs and CEOs will deliver the tips and tricks to realizing a successful financing process. Questions that will be raised include:

» What are the steps to prepare for a financing round?

» What are the strategies for attracting, securing and structuring financing deals?

» Is there a valuation best practice for an emerging company in this complex environment?

» When to start your financing round, and when not to?

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

************************************************************

East Bay AWIS,Thursday Evening, March 25, 2010

Topic: “Careers for Scientists in the Legal Professions”

A panel discussion featuring:

Madhuri “Mani” Roy, PhD, Scientific Advisor and Patent Agent, Wilson Sonsini Goodrich and Rosati

Kathleen McCowin, JD, MS, Licensing Officer, Office of Technology Licensing,

University of California, Berkeley

Carol Mimura, PhD, Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances,University of California, Berkeley

Date and Time: Thu, March 25, 6:30pm – 8:30pm

Location: Novartis, Building X-310, 5300 Hollis Street (map)

Description

*************************************************

Optivia Transporter Webinar, Monday Morning, March 29, 2010

Topic: “Transporters for the FDA, DDI and Drug Discovery”

Moderator:

Dr. Michael Silber, Professor and Chief of Drug Discovery R&D, UCSF, formerly Roche, J&J and Pfizer

Panelists:

Dr. Les Benet, UCSF, Professor, ITC member

Dr. Peter Milner, President, ARYx Therapeutics

Dr. Xiaoxiong "Jim" Wei, Director, Clinical Pharmacology, Medpace, formerly FDA (CDER) reviewer. (weijim@, 1-513-579-9911 ext 2147)

Dr. Cuiping "Tracy" Chen, Sr. Director, DMPK, Depomed

Dr. Caroline Lee, Research Fellow, DMPK, Pfizer and ITC member

Dr. Dallas Bednarczyk, Principal Scientist and Study Director, Optivia

Date and Time:  Monday, March 29, 2010, 10:00 AM (Pacific) / 1:00 PM (Eastern) / 18:00 (UK) / 19:00 (CET) / 2:00 AM (Tokyo)

Free registration: 

Topic Description

Please attend our panel discussion on the use of transporters in drug discovery and development by experts with experience at the FDA, pharma and academia.

Topics include:

* Transporters in drug discovery and development.

* The recent Transporter White Paper from the ITC (FDA, pharma, academia) and the 2006 FDA draft Guidance on DDI.

*  Strategies for in vitro transporter studies.

*  Q&A

Panelists:

Experts from pharma, academia and former FDA CDER reviewer, including ITC Transporter White Paper authors (see below for details).

Who Would Benefit:

*  Drug discovery and development management

*  Drug discovery and development scientists

*  Government Agency scientists

*  Regulatory professionals

*  Consultants

Additional Information:

The Transporter White Paper from the ITC (FDA, pharma, academia) was published recently in Nature Reviews - Drug Discovery.  The ITC consists of members from the FDA, pharma and academia.  The white paper states that it is intended to be used in conjunction with the 2006 FDA draft Guidance on DDI.

The Transporter White Paper and a brief Road Map summary are available at whitepaper.html.  The Road Map summarizes key sections and serves as an index to quickly navigate to them in the White Paper.

**********************************************************************

Bio2Device Group, Tuesday Morning, March 30, 2010

Topic: “Product Life Cycle Management in Medical Devices” 

Speaker: Barbara Sue (Susie) Faries, MBA, CEO, SciMed Partners Inc.

Date and Time: Tuesday, March 30, 2010, 8:30 – 10:30 am

Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)

Cost: Free

Parking: On street and in NOVA and library parking lots across the street.

Topic Description

Experience has shown that effective life cycle management (LCM) is

critical to maintaining customer satisfaction, while minimizing waste and

expense. This presentation guides attendees through the critical moments of the

medical life cycle, beginning with the introduction of a new product, the

"maintenance" of the product during its core lifetime, and finally, the

obsolescence and likely replacement of the product in the field.

The presentation covers:

• Definition of life cycle management

• Required coordination of multiple departments

• How customer focus is the first requirement

• Roles of involved departments

• Implementation of effective life cycle management

Speaker Bio

Ms. Faries is CEO of SciMed Partners. SciMed, headquartered in the Bay

Area, helps established companies, potential investors, and entrepreneurs

assess markets, technologies, and intellectual property in the scientific and

medical arenas. SciMed focuses on medical devices, medicine, biotechnology,

pharmaceuticals, and emerging technologies.

“Susie” has held senior executive level positions with major US

corporations including Vice President of Marketing for American Medical

Response, the largest provider of emergency medical services in the US ($1

billion in revenue) and Vice President of Marketing for American Medical

Pathways, the technology subsidiary of American Medical Response. She has

worked in large and start-up environments in medical devices and health care

technologies. She is the former CEO of SMS Healthcare, headquartered first in

Virginia then Denver, with offices in North Carolina and West Virginia. She

comes from a family of entrepreneurs that has an 89-year track record of

successful business operations.

**********************************************************

San Jose State University Biomedical Engineering Society, Tuesday, March 30, 2010

Event: Bay Area Biomedical Device Conference 2010

Speakers:

• Julian Nikolchev, Founder & CEO, Pivot, Inc.

• Rob Abrams, Operating Partner, Sanderling Ventures

• Tom Bauer, M.D., Ph.D., The Cleveland Clinic Foundation

• Larry Eiselstein, Ph.D, P.E., Exponent, Inc.

• Raj Makkar, M.D., Ph.D., Cedars’ Sinai Medical Center

• Jeffrey Lotz, M.D., Ph.D., Professor, University of California, San Francisco

Date and Time: Tuesday, March 30, 2010, 8:00 am – 5:00 pm

Location: Engineering Auditorium at SJSU

For details and on-line registration, go to:



Cost:

• $195 Early Registration

• $245 Late Registration (After 3/17/2009)

• $275 Walk in registration

• $40 SJSU Students

• $75 Non-SJSU Students

Event Description

The Organizing Committee has identified and invited a set of outstanding

speakers who will address several areas that are critical to the biomedical

device industry.  There will be presentations on interventional cardiology,

device explants, corrosion of implants, intervertebral disc degeneration and

regeneration, appropriate selection of animal models for clinical trials,

regulatory affairs and entrepreneurship pertaining to medical devices.  This

event will not only cover technologically significant advances in the field,

but will also serve as a networking opportunity.

**********************************************************************

MD&DI Free Webinar, Tuesday Morning, March 30, 2010

Topic: Technology Trends: The Quest for Innovation

[pic]Panelists for the Webcast include:

Larry Schmitt, President and Founder,Inovo

John Bashkin,VP strategic business development,Triple Ring Technologies ( Newark, CA)

Jim Best, Founding Partner and Principle,Pensa

Moderated by: Heather Thompson, Managing editor,MD&DI

Date and Time: March 30, 2010, 11:00 am – noon PT

Cost: Free

Register at:

Topic Description

What does it mean to be innovative? How can medical device manufacturers adopt innovation programs to create successful products? This Webcast seeks to provide answers by exploring available innovation models that are currently in use in this and other industries. Experts provide the latest ideas in developing and creating medical devices using such models. They also explore avoiding common pitfalls and how to implement an innovation model into a busy lifecycle process.

See details at

Note you can view this webcast at later time by returning to website.

See replay of excellent Topic: “The Medtech Marketplace in 2010”

Moderated by:Sherrie Conroy, Director of Content, Medical Device Brands

Topics and Speakers:

• “New Product Development & Launch Strategies - The Next Era in Medtech, ”Rebekkah Carney, MIM, Associate Vice President, MedSurg Insight, GfK Healthcare

• Topic: “Transactions in the Medtech Space,” John L. Babbit, Transaction Advisory Services, Ernst & Young

****************************************************************

Free UCSC Extension Bioscience Program, Tuesday Evening, March 30, 2010

Topic: Bioscience Program Information and Q&A Session

Instructor: Michelle Ragozzino, Ph.D., Program Director

Date and Time: Tuesday, March 30, 2010, 6:30 – 8:00 pm

Location: 2505 Augustine Drive, Santa Clara, CA

Cost: No fee but enrollment required

Register at ucsc-extension.edu

Course Description:

This free evening event is an informal discussion geared towards new or returning students interested in one or more of the Bioscience certificate programs. Led by the director of the Bioscience programs, the event begins with a short overview of the five Bioscience certificates, followed by an open-floor segment for audience questions.

[pic]***************************************************************

BioDesign, Tuesday Evening, March 30, 2010

Topic: From the Innovator’s Workbench

Speaker: Lonnie Smith, Chairman of the Board and Chief Executive Officer, Intuitive Surgical, Palo Alto, CA

Date and Time: Tuesday, March 30, 2010, 5:30-6:30 pm with reception to follow

Location: Vidalakis Dining Room, Schwab Res Ctr, Stanford Graduate School of Business (see about parking)

Stanford faculty, students and staff: To register, send an email to biodesign@stanford.edu from your Stanford email account. For all others, register at

|General Admission |[pic]$ 45.00 |  Limit: 80    Available: 44 |

|Stanford Alumni |[pic]$ 35.00 |  Limit: 60    Available: 42 |

Topic Description

From the Innovator's Workbench

From the Innovator's Workbench features top innovators in the biomedical technology field, interviewed by David Cassak. In this series you'll hear them discuss their process of

• identifying major critical needs

• creating new technologies

• implementing innovations in patient care

The Workbench events serve several purposes, first, to showcase the people who have built the industry and expose the community to their story and lessons learned. In addition, we seek to provide a networking opportunity for the medical device community.  There is an opportunity following the interview to network with others in the field: VCs, attorneys, industry professionals.

Speaker Bio

Mr. Smith joined Intuitive in June 1997 from Hillenbrand Industries, where he was Senior Executive Vice President. Mr. Smith joined Hillenbrand in 1978 and during his tenure he was also a member of the executive committee, the office of the president and the board of directors. Mr. Smith has also held positions with The Boston Consulting Group and IBM. Mr. Smith received his BSEE from Utah State University and an MBA from Harvard Business School.

************************************************************

Science/UCSF Biotech Career Day, Thursday, April 1, 2010

Event: Science/UCSF Biotech Industry

Career Day

Date and Time: April 1, 2010, Workshops: 10:00 a.m. - 4:00 p.m.

Recruiters available: 1:00 p.m. - 4:30 p.m

Location: UCSF Mission Bay Campus - Genentech Hall, 600 16th Street, San Francisco, CA

Cost: Free to attendees; open to all; no registration required

Visit the Mission Bay campus for a chance to get valuable advice from career experts and to meet face to face with recruiters from some of the world's top scientific organizations. Don't miss this opportunity to connect with staffing professionals and hiring managers from the companies you want to work for.

Science and UCSF are teaming up to bring you a unique biotech day that includes five career development workshops and a chance to meet face to face with recruiters.

Details at

Workshops:

• Industry Career Paths - 10:00 a.m. - 11:30 a.m.

(Brianna Blaser, Project Director for Outreach, Science Careers/AAAS, and panel)

Join us for a panel discussion with Ph.D.-level scientists who work in industry. Bring your questions to learn more about the opportunities in industry, the skills needed to succeed, and how to transition to your first year on the job.

• Transitional Education/Training for Alternative Careers in Science - 11:45 a.m. - 12:45 p.m.

(Victoria Sharma, Program Director for Bioscience, UC Berkeley Extension)

Transitioning to a new career can be daunting, but getting the latest up-to-date training can give you a leg up on the competition. Explore new training options for various bioscience careers such as clinical and regulatory sciences and biopharmaceutical business.

• Making Connections: Networking and Career Fairs - 1:00 p.m. - 2:00 p.m.

(Brianna Blaser, Project Director for Outreach, Science Careers/AAAS)

This presentation will teach you the basics of good networking and how to employ those tactics in a career fair setting. Strategize about how to make the most of a career fair, how to introduce yourself, and what to do after the event is over. Using the techniques you learn will help you make the most of the career fair.

• Job Hunting in the Biotech Industry - 2:15 p.m. - 3:30 p.m.

(Bill Lindstaedt, Director, Office of Career and Professional Development, UCSF)

Learn how to prepare resumes and cover letters for your industry job search. Also, you will learn about job search strategies necessary for success on the biotech/pharma job market along with some tips for interview success and effective negotiations after you receive your job offer. After this seminar you will understand how to apply the four job hunting techniques that comprise a comprehensive job search in the biotech industry.

• Q&A: An Open Forum with UCSF Career Counselors - 3:30 p.m. - 4:00 p.m.

How to Prepare for the Career Event

You will need to bring several copies of your resume/CV for recruiters who may request them. Read Making the Most of Career Fairs for good advice.

**************************************************************

Triple Ring Technologies, MedTech Frontiers, Wednesday Evening, April 1, 2010

Topic: “The Role of Medical Robotics in the Treatment from Cancer to Hair Transplantation”

Speaker: Dr. Mohan Bodduluri, Co-Founder and VP of R&D, Restoration Robotics

Date and Time: April 1 2010; 6:00 – 6:45 PM Refreshments

6:45 – 8:00 PM Presentation & Questions

8:00 – 9:00 PM Networking & Consultations

Location: Triple Ring Technologies, Inc.

39655 Eureka Drive Newark, CA 94560 (510) 592-3000

Cost: Free but registration is required. Go to

Topic Description

The event on April 1 will feature Dr. Mohan Bodduluri, co-founder and VP of R&D at Restoration Robotics. Dr. Bodduluri was previously VP of R&D at Accuray, where he helped develop the Cyberknife system. His presentation will focus on various technologies, such as image processing, machine vision, and robotics, that have to come together to be effective in the highly regulated field of medical devices.

In particular, the talk will focus on the two companies the speaker has been involved in, Restoration Robotics and Accuray.

*****************************************************************

Northern California Chapter, ACRP, Thursday Evening, April 1, 2010

 

Topic: “Top Ten Intellectual Optical Illusions in Clinical Research”

Speaker: Richard Chin, M.D, CEO Institute of One World Health, San Francisco, CA

Date and Time: Thursday April 1, 2010 6:00 – 9:00 pm 

Agenda:

6:00 – 7:00 PM Registration sign-in, Networking, & Dinner Buffet

7:00 – 7:30 PM Welcome, Announcements, "OPEN MIC" for job referrals

7:30 – 8:45 PM Educational Program

8.45 – 9.00 PM Q&A

Location: The Institute for One World Health, 50 California Street, Suite 500, San Francisco, CA 94111

Cost:

|NCC ACRP member |Free |

|ACRP member |$10 |

|Non-member |$15 |

See further about contact hours, etc. and other details at

EVENT REGISTRATION before Monday, 29 March 2010 11:59PM PST

Register early to assure admission; at event IF space available (+$5.00 nonmember)

REGISTER? NOW – or click Northern CA Chapter

Topic Description

As recent work by Kahneman have demonstrated, there are certain cognitive shortcuts that human brain takes when examining data and making decisions. Clinical trial results are particularly prone to such "intellectual optical illusions" because primate brains are not hardwired to interpret large amounts of aggregate statistical data. This lecture will explain some of the most common mistakes in clinical trial interpretations such as regression to the mean, subgroup analysis based on dependent variables, and common paradoxes in clinical data.

Speaker Bio

Richard Chin received a B.A. in Biology, magna cum laude, from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes Scholarship. Dr. Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California. He previously served on the Adjunct Clinical Faculty of Stanford University School of Medicine and currently serves on the Boards of Directors of RXi Pharmaceuticals, a company founded by Craig Mello developing novel RNAi based treatments for human diseases, and of Genmedica Therapeutics, a leading biotech company in Spain developing innovative treatments for diabetes.  Dr. Chin joins One World Health from OXiGENE, where he served as President and Chief Executive Officer. Previously, Dr. Chin served as Senior Vice President and Head of Global Development for Elan Corporation, where he had worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. Dr. Chin has also held various clinical and scientific roles for Genentech, Inc. including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech, and began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. Richard Chin, M.D. Chief Executive Officer, is an Internist with extensive expertise in drug development. He has overseen over 40 Investigational New Drug (IND) Applications for new molecular entities and new indications, as well as eight New Drug Applications (NDAs)/Biologic License Applications (BLAs), and has authored a major textbook on clinical trial medicine.

 

Program Objectives:

Understand regression to the mean

Understand proper use of p value

Understand pitfalls of subgroup analysis 

Target Audience:

Clinical Research Professionals

Sponsor Organizations

Study Site Investigators & Coordinators

Independent Consultants

Students of Clinical Research

Academic Medical/Clinical Researchers

Service Providers/Vendors

Institutional Review Boards

Quality Assurance

 

**************************************************************

FountainBlue, Friday Morning, April 2, 2010

Topic:” FountainBlue's Funding Road Trip: Perfecting Your Pitch to Investors”

Speaker: Bill Joos, principal of "Go To Market Consulting

Date and Time: Friday, April 2, 8:30 a.m. - 1:00 p.m.

8:30    Registration and Networking, in the Cooley Café

9:00    Bill Joos: Perfecting Your Pitch to Investors, in the Cooley Café

10:30  Morning Break

10:45  Pitch Practice Sessions - 15 mins a team

1:00   Optional Pitch Debrief Meeting

1:30   Adjourn. Please note that we have the room until 1:45 p.m. and we welcome you to stay to network with fellow entrepreneurs.

Location: Cooley Godward Kronish LLP, 3175 Hanover, Palo Alto

Audience: Early-Stage, Funding-Bound Clean Energy, High Tech and Life Science Entrepreneurs and Intrapreneurs, who have attended our October and/or our November workshops

Cost for 1 or 2 Entrepreneurs: $83 for FountainBlue members, $93 for Partners, $103 General

On-Site for members is $103 and $124 and for non-members.

Registration: Please pre-register by noon on 3/31 using the PayPal link at .

Topic Description

FountainBlue cordially invites high tech, life science and clean energy entrepreneurs to the second funding preparation workshop entitled 'Perfecting Your Pitch to Investors'. This hands-on workshop, which follows the first workshop entitled 'Your Company's Value Proposition', will take entrepreneurs through the process of creating and delivering a compelling elevator pitch, a one-page executive summary and a 13-15 slide company overview presentation. Attendance at one of the two workshops in the series is a pre-requisite to attending our third and final workshop in the series, 'Your Meeting with Investors', which features feedback from active investors.

 

For this workshop, working in partnership with fellow entrepreneurs in similar, non-competing spaces, participating entrepreneurs will have the opportunity to learn best practices and immediately apply these learnings to their own companies. Whether you are a serial entrepreneur, or someone who may be considering a future opportunity, you are sure to benefit from the information presented, the connections made and the peer-to-peer knowledge shared.

Speaker Bio

Bill Joos is the principal of "Go To Market Consulting", based in Palo Alto, CA. He works with early stage startups, venture capital firms and their portfolio clients. Most recently he spent 6 years as the VP of Entrepreneur Development at Garage Technology Ventures, an early stage venture capital firm that he co-founded along with Guy Kawasaki. His reputation at Garage was that he provided their clients with effective, hands-on, action-oriented strategic and tactical mentoring and coaching. Bill has worked with literally hundreds of early-to-mid stage startups and helped them polish and clarify their messages and refine their fund-raising and customer presentations; but his contributions to them extended well beyond being a "Pitch Doctor". He has mentored and coached them in go to market strategies, revenue and pricing optimization, business alliances, business development, partnerships, and marketing. Over 15,000 entrepreneurs worldwide have attended conferences where Bill has been a featured keynote speaker on various entrepreneurial topics. He has held sales and marketing positions with a variety of companies, including IBM and as a VP of the software division of Apple Computer.

*******************************************************************

Bio2Device Group, Tuesday Morning, April 6, 2010

Topic: “Self-guided Surgery”

Speaker: John Black, Ph.D., VP, Imaging, Avinger Inc.

Date and Time: Tuesday, March 16, 2010, 8:30 – 10:30 am

Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)

Cost: Free

Parking: On street and in NOVA and library parking lots across the street.

Topic Description

The introduction of the laser as a therapeutic surgical tool in the 1960's has had a profound effect on certain fields of medicine, particularly in ophthalmology and more recently in minimally invasive surgical disciplines such as urology. The use of laser-based optical diagnostic tools, both as stand-alone devices and coupled to other instruments has recently started to blossom as many of the advances in electronics, computing and optical telecommunications of the last decade make their way into the biophotonics field. The enabling features of light-based diagnostics include the ability to use fiber-optics, sometimes with outer diameters as small as 50 microns as conduits for information, the extremely high intrinsic bandwidths and signal-to-noise of optical systems, and the possibility of using both the spectral and coherence properties of laser light to yield simultaneously both functional (molecular level) and structural (tissue organization) information.

John will present a tour of how optical techniques available today can be used to sense temperature, pH, and force, and show how the optical analog of ultrasound, Optical Coherence Tomography, is being used to equip surgical instruments with the ability to allow the physician to image the tissue they are interacting with and to make a treatment decision in real time, with 10-micron precision, all with minimal mechanical and cost impact on the surgical tool. Examples from thermal coagulation (ablation) and intravascular plaque excision will be discussed.

Speaker Bio:

John Black has 16 years of experience in the medical, commercial and research segments of the photonics industry. At Avinger, he leads the engineering effort in the development of image-guided catheters for the treatment of peripheral and coronary artery disease. Prior to Avinger, he led the optical engineering team at FoxHollow Technologies in the successful development of the first-in-man intravascular real-time image-guided plaque excision catheter (Nighthawk™). .

At Coherent Medical he was the manager of the Laser / Tissue Engineering group spearheading the development of flagship surgical, ophthalmic and dermatologic applications of lasers. While at Coherent he pioneered a new treatment of cutaneous vascular lesions which led to the development of the Cynosure Cynergy™ Vascular Workstation (unfortunately not the Coherent Cynergy Vascular Workstation). Also at Coherent he co-discovered the first laser-activated intravascular blood-pool MRI contrast agent. After Coherent he joined Lightwave Electronics (now JDSU, Inc.) working initially on advanced fiber lasers for RGB projection systems in consumer electronics ( ), and subsequently on the laser design for the industry-leading Xcyte™ mode-locked ultraviolet laser for flow cytometry.

John has a B.Sc. in Chemistry with First Class Honors and a Ph.D. in Physical Chemistry from the University of Nottingham. He received the T.J. King Memorial Prize for undergraduate physical chemistry research and an SERC / NATO Research Fellowship to do post-doctoral research in photochemistry at Stanford University. He was also a post-doctoral research fellow at Columbia University developing new lasers for molecular spectroscopy and reaction dynamics. He has lectured widely both in the US and abroad on laser spectroscopy and applications in medicine, and has several well-cited publications in these areas. John has 4 issued patents and several pending applications in the fields of laser development, trans-dermal cardiac output monitoring, optical diagnostics, and medical devices. He is a Senior Member of the IEEE, and a member of OSA, APS, SPIE and Sigma Xi. He has also been a Guest Lecturer at the University of Arizona Biomedical Engineering Program, and is a peer-reviewer for several high-impact journals including Optics Express, Optics Communications, Lasers in Surgery and Medicine and the Springer “Series in Optical Sciences” books.

********************************************************************

Stanford Center for Law and the Biosciences, Friday, April 9, 2010

Topic: “Drug Development and International Access”

Speakers Include:

• Gregg Alton, Executive Vice President, Corporate and Medical Affairs at Gilead

• Tom Bollyky, Fellow at the Center for Global Development

• Robert Chess, Chairman, Nektar Therapeutics; Board member and initial Chairman, Bio Ventures for Global Health

• Richard Chin, CEO of OneWorld Health

• Joe Damond, Vice President of Government Relations at Pfizer

• Charlie Kinzig, Vice President of Corporate Intellectual Property at GlaxoSmithKline

• Carol Mimura, Assistant Vice Chancellor, UC Berkeley Intellectual Property & Industry Research Alliances

• Jenik Radon, Professor at Columbia University's School of International and Public Affairs

• Hannu Wager, Counselor in the IP Division of the WTO, and Secretary of the WTO TRIPS Council

Date and Time: Friday, April 9, 2010, 9:00 am – 2:00 pm

Location: Stanford Law School

Cost: Free 

This event is free and open to the public. For more information, please contact Kelly Lowenberg at klowenberg@law.stanford.edu or visit the event website. Register at

Topic Description

Many life-threatening diseases disproportionally affect people in low-income and middle-income countries. Even when treatments exist, many people are unable to afford essential medicines needed for survival. While patent protection for new medicines is necessary to incentivize drug research and development, in developing countries, these patents prevent price-lowering competition.

Professor John Barton, a member of the Stanford Law School faculty for 40 years, devoted the latter part of his distinguished career to increasing access to medicine while continuing to provide incentives for drug development. In 2008, Professor John Barton and Pfizer CEO Jeff Kindler proposed a new international framework on drug pricing, favoring IP exemption for the poorest countries, an international drug approval process, divided markets in middle-income countries, and trade agreements among developed countries to ensure policies recognize and reward innovation.

In tribute to Professor Barton's work and his dedication to increasing access to medicine, this conference aims to discuss some of the innovative new business models and intellectual property strategies, including Professor Barton's proposal, which will make it possible for more patients to have access to life-saving medicines. Speakers will discuss business strategies to incentivize research and development, models to reduce the cost of drug development, and intellectual property, regulatory, and pricing structures effecting access to medicine.

********************************************************************

Bio2Device Group, Tuesday Evening, April 13, 2010

Topic: “A Serial Entrepreneur's Journey- How a Physicist became a Leading Device Innovator”

Speaker: Hira Thapliyal, Ph.D., President and CEO, VytronUS, Inc.

Date and Time: 4/13/2010, 6:00 pm

Location: TIPS, 1000 Elwell Ct., Suite 150, Palo Alto, CA

Cost: 

$6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only

$20 - Late Registration and Non-Members

$25 - Walk-ins

Register online at

Topic Description

Hira Thapliyal will discuss his journey from a physicist to a leading serial entrepreneur in Silicon Valley/USA. He will discuss the highs and lows, and some lessons he has learned along the way. Along his successful career path you will see familiar companies that he has lead and/or founded such as DVI, CVIS, Arthrocare, Tescient, MicroBionics, and VytronUS.

Speaker Bio

Dr. Hira Thapliyal, Ph.D., got started in the medical device industry while developing a cauterizing, glass scalpel. A cardiovascular industry veteran, who played a critical role in the founding of companies such as atherectomy pioneer DVI (Devices for Vascular Intervention Inc.), and intravascular ultrasound leader CVIS (Cardiovascular Imaging Systems, now part of Boston Scientific Corp.). Three years later he became CEO of MicroBionics, Inc. Thapliyal then founded a new company in April 1993 called ArthroCare Corporation, which used coblation technology to facilitate arthroscopic joint surgery. Dr. Thapliyal served as the company's initial president and chief executive officer.

Hira then co-founded and was CEO of Tescient, Inc. Hira is currently the President & CEO of VytronUS, Inc. VytronUS is developing products in cardiovascular field.

Hira is currently a member of the Board of Directors for Apsara Medical, Inc., Intact Medical, Inc., and PAVAD Medical, Inc. He is also the Special Partner of MedVenture Associates IV. Dr. Thapliyal is also an Advisory Board Member to the Department of BioEngineering at University of California, Berkeley and Materials Science and Engineering at Cornell University.

Dr. Hira Thapliyal earned his B.S. in electrical engineering from Washington State University, followed by an M.S. in electrical engineering from the University of Idaho and a Ph.D. in materials science and engineering from Cornell University.

**********************************************************************

Bioscience Business and Marketing Essentials, Thursday and Friday, April 15-16, 2010

2-Day Intensive Course: Bioscience Business and Marketing Essentials, Thursday and Friday, April 15-16, 2010 with 2 months to complete project

Lead Instructor: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and

Expert Guest Speakers:

▪ Donald Holsten, Pharm. D., Regulatory Consultant and Educator

▪ Bev Hudson, MBA, General Manager, Clinical Research Services, MedPoint Communications, Inc

▪ Julie Tompkins, MBA, Sr. Vice President, Timely Data Resources (TDR)

Please see ucsc-extension.edu/biobusiness for complete biographies

Date & Time: April 15-15, 2010, Thursday and Friday, 8:30am-5pm

Location: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara, CA 95053

Fee: $750; $675 through April 1

Topic Description

The bioscience industry is like no other. Lengthy timelines and unique financial, legal, regulatory, social and political challenges impose constraints that impact every aspect of the business. This course helps participants gain: a practical understanding of the bioscience industry landscape, key business drivers and challenges; insight into the critical roles that business and marketing disciplines play at all stages of a bioscience company's development; and hands-on experience implementing important bioscience business processes that are essential to success within the industry. Two days of intensive classroom are followed by 2 months to complete individual project with guidance of instruction and access to research resources.  For more information: See ucsc-extension.edu/biobusiness.

Instructor Bio

Audrey Erbes, Ph.D., Principal of Erbes & Associates and , is a marketing consultant with more than 30 years of managerial experience in marketing and business development in the biotech and pharmaceutical industries. She was Executive Vice President and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan and before that held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad.

**********************************************************************

BayBio NEST Venture Spotlight, Thursday Morning, April 15, 2010

Topic: “A Tailor Made Approach: Personalized Medicine”

Panel Moderator: Jeff Peterson, CEO, Target Discovery

Panel Speakers: Bill Gerber, Bay City Capital

Date and Time: April 15th, 2010, 8:00 – 10:00 am

Location: Latham & Watkins, Menlo Park Campus, 140 Scott Dr., Menlo Park, CA 94025

Cost: Early Bird Registration through March 13th:$19.00;On-Site Registration, March 15th:$29.00

Register at

(If you are an employee of a Sponsor company, please contact

Program Manager, Jessica Knowles to obtain your complimentary registration.)

Topic Description

The crisis of health care economics is now frighteningly familiar to us all, driven by advancing technology often coupled with increasing cost. Personalized Medicine is our greatest hope for remediation of this rising economic tsunami. Decades of advances in molecular biology are now delivering important new diagnostics for Personalized Medicine (PMDx) to determine the patient's response, resistance or toxicity risk before or during treatment, in order to optimize the selection of medical treatments from amongst the alternative options. Patients benefit enormously by not wasting valuable months of treatment time and not undergoing the side effects and physical insult of ineffective or toxic treatments like chemotherapy in cancer.

The BayBioNEST Venture Spotlight Series is a unique forum that allows investors to speak directly to entrepreneurs in a reverse pitch format. Investors and experts have a platform to discuss their current interests, target markets, therapies and technologies, as well as the maturation level of investment targets. The Venture Spotlight Series is a breakfast panel discussion with time for Q&A and networking.

******************************************************************

San Jose BioCenter, Thursday Morning, April 15, 2010

Topic: “Effective outsourcing: Navigating hurdles and avoiding pitfalls in virtual drug development”

The panel will include:

• Dr. Kate Hanham, President & Founder, Mentara, Inc.: Mentara is a consulting consortium of highly qualified drug/device discovery and development professionals.

• Richard Lin, President, Explora Biolabs, Inc.: Explora BioLabs provides vivarium and pre-clinical in vivo contract research services.

• Dr. Fred Aslan, Vice President, Venrock: an investor experienced in starting and running virtual companies.

• Dr. Michael Chang, Vice President, Research & Development, Limerick BioPharma: an executive using the virtual development model.

• Toni Foster, former Senior Director, Clinical and Project Management, Biovascular: an expert with over 17 years of experience and over 45 clinical drug trials managed

Date and Time: Thursday, April 15, 2010 | 11:30am-1:30pm

Location: The San Jose BioCenter, 5941 Optical Court, San Jose, CA 95138

Space is limited for this event, so early pre-registration is recommended to avoid disappointment on the day!

• Regular Price: $30

• Partners' Network: $20

• BioCenter Members: Free (RSVP to Aurélie)

• On-site Registration: add $10 to the above

Register at

Topic Description

Virtual drug development promises savings of time and cost in the development of new drugs and devices.  In order to realize this promise, managers and executives may need to learn some new tricks!  In this session a panel of experts with different perspectives on the virtual development experience will discuss some of the advantages and challenges of the virtual model. 

Virtual drug development promises savings of time and cost in the development of new drugs and devices. In order to realize this promise, managers and executives may need to learn some new tricks!

In this session a panel of experts with different perspectives on the virtual development experience will discuss some of the advantages and challenges of the virtual model. *******************************************************

CACO Workshop, Monday Afternoon, April 19, 2010

Date and Time: Monday, April 19, 2010, 12:45 – 5:30 pm

Event Topic: Drug Transporters: Interpretation and Application of the International Transporter Consortium Whitepaper and Draft FDA Guidance

Speakers: Joseph Polli (GSK), Caroline Lee (Pfizer), Harma Ellens (GSK), Xiaoyan Chu (Merck) Location: Bay Area: Foster City Crowne Plaza

Event fee: $1 for unemployed; For others, details available upon online login.

Major Sponsor: (1)Qualyst, Inc.

Vendor show vendors registered to date: (11)Absorption Systems; Applied Biosystems; BD Gentest; CellzDirect; Celsis In Vitro Technologies; Enthalpy Analytical; MicroConstants, Inc.; Optivia Biotechnology; Quotient Bioresearch; Vitalea Science, Inc.; XenoTech, LLC

Online registration and further details:

Registration deadline: 4/16/2010  (it will close sooner if the seating cap is reached)

Additional Details: caco-

**************************************************************************

FountainBlue Life Science Forum, Monday Evening, April 19, 2010

Topic: “Physician's Panel: Partnering with Entrepreneurs to Better Address Patient Needs”

Date & Time: Monday, April 19 from 5:30 - 7:30 p.m.

Location: Bay Cafe Clubhouse, 1875 Embarcadero, Palo Alto

Cost: $21 members, $32 partners, $42 general

On-Site Registration is $42 for members, $52 for nonmembers, or $124 for FountainBlue Ongoing membership and admission

Registration: Please pre-register by noon on the Friday prior to the event using the PayPal link at .

Audience: Life Science entrepreneurs, intrapreneurs and investors, no service providers please

Facilitator KPMG to be confirmed

Panelist D. Christopher Chung, M.D., Vice President, Medical Affairs, R&D, and Engineering, Natus Medical

Panelist Michael Leong M.D., Interim Executive Director, Pain Center Stanford

Panelist Brian Wilfley, Chief Scientist and co-Founder, Triple Ring Technologies

Presenting Entrepreneurs to be confirmed

Topic Description

Physicians are feeling the pressures of the changing policies, economies and technologies, which is influencing how they run their practices, and how they work with their patients. Our panel this month will feature physicians who are partnering with entrepreneurs, intrapreneurs and investors and proactively facing these changes, and a set of entrepreneurs who are developing solutions to support physicians in addressing these issues.

Panelist Bios

Facilitator from KPMG to be confirmed

Panelist D. Christopher Chung, M.D., Vice President, Medical Affairs, R&D, and Engineering, Natus Medical

D. Christopher Chung, M.D., has served as our Vice President R&D and Engineering since June 2003, and has served as our Vice President Medical Affairs since February 2003. Dr. Chung also served as our Medical Director from October 2000 to February 2003. From August 2000 to present, Dr. Chung has also served as a Pediatric Hospitalist at the California Pacific Medical Center in San Francisco. From June 1997 to June 2000, Dr. Chung trained as a pediatric resident at Boston Children's Hospital and Harvard Medical School. From May 1986 to July 1993, Dr. Chung worked as an Engineer at Nellcor, a medical device company. Dr. Chung holds a Bachelor of Arts degree in Computer Mathematics from the University of Pennsylvania and a Doctor of Medicine degree from the Medical College of Pennsylvania-Hahnemann University School of Medicine. He is board certified in Pediatrics and is a Fellow of the American Academy of Pediatrics.

Panelist Michael Leong M.D., Interim Executive Director, Pain Center, Stanford University

Michael Leong, MD is a Pain Medicine Specialist in Los Gatos, CA and Interim Executive Director of the Pain Center at Stanford University Pain Management Center. He was involved with clinical research in novel pain analgesics, particularly Prialt (intrathecal Ziconotide). Dr Leong has been a Medical Director in the Pharmaceutical industry, most recently at XenoPort, Inc.

Michael holds a Doctor of Medicine from Georgetown University Medical School and  completed his Anesthesiology residency and fellowship at Stanford University. He is board certified in Anesthesiology and Pain Medicine and is the author of about 30 publications.  Dr Leong's main interests involve integrating academic teaching, clinical practice, and novel drug and device therapies for chronic pain.

Panelist Brian Wilfley, Ph.D., Director, Chief Scientist, Triple Ring Technologies

Dr. Brian Wilfley has over 20 years of experience leading development efforts for medical device and instrumentation companies. He has held senior scientific and engineering positions with Resonex, Inc., Park Scientific, Inc., Signature Bioscience, Inc., and NexRay, Inc. Combining a broad theoretical background with a highly developed experimental sense, Brian  has experience across the full range of challenges encountered in developing complex measurement-based products. He is able to support the basic research and development of measurement-based equipment, as well as the detailed engineering required to implement it. His  experience ranges from magnetism to x-rays, and includes a broad array of applications including biotech instrumentation, medical imaging, and optical inspection.

Brian is a co-inventor of six issued patents and has authored a number of technical papers. He received his AB in Physics from the University of California at Berkeley and his Ph.D. in Physics from the University of California at San Diego.

Presenting Entrepreneurs to be confirmed

***********************************************************************

Bio2Device Group, Tuesday Morning, April 20, 2010

Topic: tba

Speaker: David DeNola

Date and Time: Tuesday, April 20, 2010, 8:30 – 10:30 am

Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)

Cost: Free

Parking: On street and in NOVA and library parking lots across the street.

******************************************************************

Pharmaceutical Executive, Free Webinar, 8:00 am PT April 20, 2010

Topic: “The Future of Commercial Models in Pharma”

Presenter:

Chris Nickum, Vice President, Practice Leader, Commercial Effectiveness, IMS Health

Patrick J. Retif, Global Leader, Commercial Effectiveness, Center of Excellence,IMS Health

Moderator: William Looney, Editor-in-Chief, Pharmaceutical Executive Magazine

Register for this FREE Webcast!

Date and Time: Tuesday, April 20, 2010, 8:00 am PT

Topic Description

Today, many pharmaceutical executives are asking:

How will we compete in a marketplace that, by 2015, will be 80% undifferentiated?

What industry imperatives do we need to address in the design and implementation of our new commercial model?

What does our organization need to do now in order to compete?

Get the answers to these questions and more at the April 20 webcast, “The Future of Commercial Models in Pharma,” where you’ll hear IMS experts describe how your organization needs to align with the market and organize for the future in order to design, and implement, the most efficient and effective commercial model.

Through our work with leading pharmaceutical companies around the globe, IMS has identified key imperatives that the industry must address in order to ensure a successful commercial model in the future.

Whether you’re currently implementing a new commercial model or not sure where or how to get started, don’t miss this opportunity to learn more about how to best position your organization for success. Register today!

You’ll leave this webcast with:

A keen understanding of how your organization’s progress in implementing a new commercial model compares with your peers and how current trends are shaping the future

Insight into which imperatives the industry must address now in order to establish successful commercial strategies

Real-world examples of best practices, as well as tips on how to get your organization moving down the right path

Who Should Attend: Leaders in commercial strategy, implementation and operations including account management, marketing, market research, sales operations, managed markets

Register at

For more information contact Jamie Carpenter - 440.915.7235

************************************************************

BioScience Forum, Wednesday Evening, April 21, 2010

Topic: TBA

Speaker: Jean Deleage, Ph.D., Founding Partner and Managing Director, Alta Partners

Date and Time: April 21st, 2010

Date and Time: Wednesday, April 21, 2010; 6:00pm - 9:00pm

6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentation

Location: The Clarion Hotel, 401 East Millbrae Avenue, Millbrae

Full info and Registration at:



Typical Cost: $50 before 11:55 PM, Monday, April 19th

$60 on-site

$35 full-time students pre-registration

$45 full-time students on-site

Acteva fees of $3 are added to the above prices Check website for latest information

Cash or check accepted on the day of the event

Parking is $2

 

Or you can pay with a check made out to "BioScience Forum" and sent to:

BioScience Forum, 1442A Walnut Street, #308, Berkeley, CA 94709-1405

Please do not mail checks later than Thursday, April 15th

If paying with check, do not complete registration with Cvent

**********************************************************************

San Jose Biocenter, Thursday All-Day, April 22, 2010

Topic: “Meet with… Amgen”

Date and Time: [pic] Thursday, April 22, 2010

Agenda

|9:00 AM - 9:30 AM |Registration & Networking |

|9:30 AM - 10:30 AM |Presentation & Q&A |

|10:40 AM - 11:30 AM |BioCenter Tour |

|11:30 AM - 12:30 PM |Lunch & Networking |

|12:30 PM - 5:00 PM |One-on-one Meetings |

One-on-one Meeting Application & Costs

• Application fee: FREE

• Registration for one company representative:

         o $175 Regular

         o $150 Partners’ Network

• Registration for two company representatives:

         o $250 Regular

         o $215 Partners’ Network

• Registration for three company representatives:

         o $300 Regular

         o $255 Partners’ Network

• Registration for four company representatives and above:

         o add $40 [or $30 for Partners’ Network] per attendee

• BioCenter Residents and Affiliates: Free

(Bio2Device Group members eligible for partner network discount; just note B2DG under affiliation)

Presentation & Q&A Costs**

• Regular Price: $40

• Partners' Network: $30

• BioCenter Members: Free (please RSVP to Aurélie)

**Includes: Presentation & Q&A session ONLY. Seating is limited for this event, so early pre-registration is recommended to avoid disappointment! Additionally, there will be no on-site registrations.

Topic Description

Emerging companies find it increasingly difficult to reach the right person when seeking funding and/or partners. Through the “Meet with…” Series, we provide emerging companies with greater access to partnering and/or financing opportunities.

In this session, Directors from Amgen will talk to potential licensees to first explain what they are looking for in a company.

After the presentation, each pre-approved attendee* will be granted a private meeting with a Director from Amgen.

*Registrations to one-on-one meetings are subject to approval of application. To apply, please send your Executive Summary by April 4, 2010 to Aurélie at aurelie@. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application. You will be notified on April 8, 2010 if your application is accepted or rejected. Registration must be completed upon approval to secure your meeting slot.

***************************************************************BayBio Institute NEST, Thursday Morning, April 29, 2010

Topic: Technology Showcase at SRI

Date and Time: April 29th, 2010, 5:30-7:30pm

Location: SRI International, 333 Ravenswood Avenue, Menlo Park CA 94025

Cost: Early Bird Registration through April 28th - $29; On-Site Registration, April 29th - $39

Register at

Topic Description

BayBioNEST invites you to join us for the first of the 2010 Technology Showcases at SRI International. The NEST Tech Showcase allows the life sciences community to get a sneak peak at the science within often before it is published or patented and is also a great opportunity for the industry community to network with scientists, entrepreneurs and with each other.

SRI International is an independent nonprofit research /development organization in existence over 60 years, whose discoveries, patents, and inventions have touched people's lives around the world!

SRI's Biosciences Division provides complete discovery and preclinical development capabilities to take drugs and biologics from Idea to IND®. Our integrated program offers the scientific, technical, and regulatory expertise needed to expedite the process. We provide target identification, lead discovery/optimization, vaccine development, neuropharmacology research in sleep and pain, microbiology, efficacy models, comprehensive toxicology, PK/ADME, formulation, analytical chemistry, cGMP manufacturing, QA, IND preparation and government grant teaming services. In its CRO business, SRI has helped its clients, partners, and the Government advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

*********************************************************************

RAPS, San Francisco Area Chapter, Friday, April 30, 2010

Topic: “Documenting Key Quality and Regulatory Processes”

Speakers:

• Grace Bartoo, PhD, RAC, CQA, chief executive officer, Decus Biomedical, LLC

• Paul Brooks, vice president healthcare solutions, BSI

• Barry Craner, director of design assurance, Boston Scientific Corporation

• Connie Hoy, vice president, regulatory affairs & quality assurance, XOFT, Inc.

• Mark Perkins, consultant, Medical Device QA and RA Consulting

Date and Time: 30 April 2010, 7:45am–4:30pm

|7:45am |Registration Opens |

|7:45am–8:30am |Registration Check-In, and Continental Breakfast |

|8:30am–11:45am |Risk Management – Barry Craner |

| |Corrective and Preventive Actions (CAPA) – Mark Perkins |

|11:45am–12:45pm |Luncheon and Networking |

|12:45pm–4:30pm |Usability Engineering – Grace Bartoo |

| |Essential Requirements Matrices – Paul Brooks |

| |Technical Files – Connie Hoy |

| |Panel Discussion and Q/A Period |

Location: Crowne Plaza Mid-Peninsula, 1221 Chess Drive, Foster City, CA 94404

|Registration:   |RAPS and ASQ members: $175.00  Nonmembers: $200.00 |

| |Note: In order for ASQ Members to register at the member rate, it is necessary to submit your registration using the|

| |registration form. |

Register:

Topic Description

Join your quality and regulatory colleagues from the ASQ Biomedical Discussion Group and the RAPS San Francisco Bay Area Chapter for a lively and informative one-day workshop on documenting key quality and regulatory processes. Experts use a mythical medical device to demonstrate by example how to prepare key documentation in the following areas:

• Risk Management

• Corrective and Preventive Actions (CAPA)

• Usability Engineering

• Essential Requirements

• Technical Files

Quality, regulatory and other industry professionals currently working in these areas will leave the program with an expanded and practical understanding of document preparation.

Note: In order for ASQ Members to register at the member rate, it is necessary to submit your registration using the registration form.

Local Contacts:

RAPS San Francisco Chapter Contact:

Michelle Ragozzino, PhD, director of bioscience programs, UCSC Extension, +1 408 861 3861

American Society for Quaility Contact:

Walter Crompton, +1 415 484 1688

**********************************************************************

Bioscience Business Development: Building Value, Thursday and Friday, June 24-25, 2010

Intensive Course: Bioscience Business Development: Building Value, Thursday and Friday, June 24-25, 2010 (2 days of classroom and 2 months to complete project guided by instructor)

Instructors: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and and and Gilbert R. Mintz, Ph.D., President of GRM Associates

Expert Guest Speakers:

▪ Harold (Hal) Etterman, MBA, Business Strategist

▪ Carolyn Feamster, MBA, VP, Business Strategy & Analysis

▪ Ginger R. Dreger, M.S., J.D., Partner, Arnold & Porter LLP

▪ Tom Gutshall, Chairman & Co-Founder of Cepheid

▪ Michael G. McCully, M.S., Director, Recombinant Capital

Please see ucsc-extension.edu/biobizdev for details

Date & Time: June 24-25, 2010, Thursday and Friday, 8:30am-5pm

Location: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara, CA 95053

Fee: $795; $715.50 through June 10

Topic Description

UCSC Extension in Silicon Valley presents a two-day intensive course that brings the breadth of the Bay Area’s biobusiness development expertise to our Cupertino classroom. Whether financing start-up activities, trying to keep pace with the current burn rate, or moving a product into the marketplace, bioscience companies, both large and small, have a critical need for business development at every stage of their evolution. Learn the key roles that business development and licensing play in the commercialization of a new product and the development of a successful bioscience company. Santa Clara, CA. For more information, see ucsc-extension.edu/biobizdev

Instructor Bios

Audrey Erbes, Ph.D., Principal, Erbes & Associates and has more than 30 years of marketing experience in the biotech and pharmaceutical industries, of which 25 years was in corporate management at Kowa Research Institute and Syntex Corporation.

Gilbert R. Mintz, Ph.D., President of GRM Associates, a biotechnology consulting firm with expertise in business development, licensing and strategic planning.

[pic][pic][pic]

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download